Tebotelimab

**Semantic type:** Amino Acid, Peptide, or Protein|Pharmacologic Substance

**Definition:** An Fc-bearing, humanized antibody-like protein that specifically recognizes the immune checkpoint molecules programmed cell death 1 (PD-1; PD1; PDCD1; CD279; Programmed Death 1) and lymphocyte activation gene-3 (LAG-3; LAG3; CD223), with potential T-lymphocyte immunomodulatory and antineoplastic activities. Upon administration, tebotelimab specifically binds to both PD-1 and LAG-3, which are both expressed on T-cells. The dual blockade of the PD-1 and LAG-3 pathways enables potent activation of a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. PD-1 and LAG-3 play key roles in suppressing T-cell activation.

**Synonyms:** - Anti-PD-1/Anti-LAG-3 DART Protein MGD013 - Bispecific DART Protein MGD013 - Dual-affinity Retargeting Protein MGD013 - MGD 013 - MGD-013 - MGD013 - PD-1 x LAG-3 Bispecific DART Molecule MGD013 - PD-1 x LAG-3 DART Molecule MGD013 - PD-1 x LAG-3 DART Protein MGD013 - TEBOTELIMAB